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Unique astrocytic cell infiltrating growth and glial tumor growth in the confined skull make
human glioblastoma (GBM) one of the most difficult cancers to treat in modern medicine.
Prognosis for patients is very poor, as they die more or less within 12 months. Patients
either die of the cancer itself, or secondary complications such as cerebral edema, herni-
ations, or hemorrhages. GBMs rarely metastasize to other organs. However, GBM recur-
rence associated with resistance to therapeutic drugs is common. Patients die shortly after
relapse. GBM is indeed an outstanding cancer model to search for potential mechanisms
for drug resistance. Here, we reviewed the current cancer biology of gliomas and their
pathophysiological events that contribute to the development of therapeutic resistance.
We have addressed the potential roles of cancer stem cells, epigenetic modifications,
and epithelial mesenchymal transition (EMT) in the development of resistance to inhibitor
drugs in GBMs.The potential role ofTIAF1 (TGF-β-induced antiapoptotic factor) overexpres-
sion and generation of intratumor amyloid fibrils for conferring drug resistance in GBMs is
discussed.
Keywords: glioblastoma multiforme, temozolomide, resistance mechanisms, cancer stem cell, TIAF1 expression,
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INTRODUCTION
Glioblastoma (GBM) is one of the cancers most resistant to treat-
ments and is associated with extremely poor prognosis. The cur-
rent standard of care includes surgery with or without combined
radiation/chemotherapy. Alternative treatment protocols and tar-
geted therapies have been applied to GBM patients, but have unfor-
tunately yielded to limited efficacies (Omuro et al., 2007; Lukas
et al., 2009). Most cancer therapies have focused on attacking the
key biological constituents that relate to the tumor growth and sur-
vival. It includes complex mechanisms of signal transduction and
gene expression that contribute to the formation of microenviron-
ment for supporting tumor growth (Omuro et al., 2007). Targeted
therapies could be complicated by interconnecting signal networks
with multiple interferences and convergences (Lukas et al., 2009).
New methods and techniques for the targeted treatment of gliomas
such as interruption of signaling pathways, nanoparticles target-
ing, and boron neutron capture therapy have been underway (Tak-
agaki et al., 2001; Desai et al., 2006; Barth et al., 2012; Nduom et al.,
2012). However, the clinical outcomes have made little progress in
malignant gliomas to date (Omuro et al., 2007). It is thus necessary
to reevaluate current strategies to find alternative approaches to
eradicate malignant gliomas, or revisit the fundamental biology to
explore the potential cancer resistance mechanisms in GBMs.
GBM CLASSIFICATION AND COMMONMARKERS
Histologically, GBMs can be derived from low-grade gliomas in
younger patients, according to the classification of World Health
Organization (WHO). Or, they can directly develop de novo in
elderly patients (Ohgaki and Kleihues, 2007). Among the com-
plex genetic pathways in the development of gliomas, oligoden-
drocyte transcription factor 2 (olig2) and vascular endothelial
growth factor (VEGF) are expressed in all high-grade gliomas
(Ohgaki and Kleihues, 2007). Therefore, classifying GBMs based
on the activation of signal pathways or mutations of genes in
the glioma-relevant pathways may help establish targeted ther-
apies. For example, alterations in the activation of epidermal
growth factor receptor (EGFR) and platelet-derived growth fac-
tor receptor (PDFGR), or loss of the RAS regulator NF1, are
frequently observed in primary GBMs (Brennan et al., 2009).
These findings implicate that these molecules as potential ther-
apeutic targets. Although these classifications do not include all
clinical GBMs, clinical trials targeting EGFR or PDFGR have
been underway. EGFR, EGFR variant III (EGFRvIII), phosphatase,
and tensin homolog deleted on chromosome 10 (PTEN), and
O6-methylguanine–DNA methyltransferase (MGMT) have been
regarded as common markers for GBMs (Camara-Quintana et al.,
2012).
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INHIBITORS OF RECEPTOR TYROSINE KINASES
AND RESISTANCE IN GBMs
Recent studies have shown that EGFR inhibitors fail to yield
significant clinical outcomes in GBM patients. Simultaneous
activation of multiple receptor tyrosine kinases (RTKs), which
generates redundant activation of phosphoinositide-3′-kinase
(PI3K) signaling, may explain for the drug failure (Fenton et al.,
2012). Tumor suppressor PTEN, a phosphatidylinositol-3,4,5-
trisphosphate 3 (PIP3) phosphatase, can be phosphorylated at a
conserved tyrosine 240 (Y240). The phosphorylated PTEN (p-
PTEN) is associated with shortened survival and resistance to
therapy with EGFR inhibitors in GBM patients (Fenton et al.,
2012). Both fibroblast growth factor receptors (FGFRs) and SRC
family kinases (SFKs) phosphorylate PTEN, and p-PTEN fails to
antagonize the PI3K signaling (Fenton et al., 2012), suggesting
that loss of control of PI3K signaling is associated with resistance
to EGFR inhibitors in GBM.
Amplification and/or mutation of a specific RTK gene in
GBMs could confer resistance to RTK inhibitors. For example,
genes encoding EGFR, platelet-derived growth factor receptor α
(PDGFRα), hepatocyte growth factor receptor (MET), and/or oth-
ers are frequently altered (Cancer Genome Atlas Research, 2008;
Huse and Holland, 2010). It is not surprising to predict the fail-
ure in therapy using small-molecule inhibitors in targeting the
mutated and/or amplified RTKs due in part to constitutive and
concurrent activations of signal pathways in GBMs (Stommel et al.,
2007; De Witt Hamer, 2010; Hasselbalch et al., 2010; Paulsson et al.,
2011). Worse, growth factors could further enhance the drug resis-
tance in subpopulations of GBM cells harboring amplifications of
EGFR and PDGFR-α genes (Szerlip et al., 2012;Wilson et al., 2012).
These observations highlight the role of RTK ligands and extensive
redundancy of RTK-transduced signaling in innate and acquired
resistance of GBMs to drugs targeting oncogenic kinases (Wilson
et al., 2012).
CANCER STEM CELLS CONFER INTRINSIC DRUG
RESISTANCE
Cancer stem cells (CSCs) are crucial in the initiation, progression,
and angiogenesis for GBMs and essentially all cancers (Wen and
Kesari, 2008; Dietrich et al., 2010). GBM CSCs express CD133 and
nestin, which are also expressed by normal stem cells or progeni-
tor cells. Whether drugs can specifically select against CSCs in the
brain without affecting normal stem cells is not quite understood
(Yilmaz et al., 2006; Calabrese et al., 2007). How CSCs develop into
highly vascular GBMs is largely unknown. Expression of Olig2
and VEGF in all high-grade gliomas and glioma stem cells may
render them highly vascular (Plate et al., 1992; Ohgaki and Klei-
hues, 2007; Takano, 2012). Anti-angiogenesis strategies to block
CSC expansion have been utilized. However, the benefit of anti-
angiogenesis therapy has been questionable in both preclinical and
clinical trials.
The failure of anti-angiogenesis therapy may be due to eva-
sive (adaptive) and/or intrinsic (pre-existing) resistance in GBM
cells (Bergers and Hanahan, 2008). Simultaneous inhibition of
cancer survival targets, along with potential escape pathways, may
have a great potential in eliminating drug-resistant cancer cells.
One such example is targeting both FGFRs and VEGF. Combined
VEGF and FGFR–Fc fusion protein (FGF-trap) treatment atten-
uated revascularization and slowed tumor growth, which indi-
cates that FGF signaling is involved in regulating angiogenesis
(Casanovas et al., 2005). It has been reported that AZD2171, a
pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor
vasculature and alleviates cerebral edema in GBM patients. This
study implies analogous evasive resistance may be mediated by
FGF-dependent revascularization (Batchelor et al., 2007). Given
that FGFRs also participate in EGFR and PDGFR-mediated can-
cer resistance, designing therapeutic regimes that simultaneously
target activation-reactivation, and amplification of FGFRs and
RTKs may be beneficial in resolving therapeutic resistance in GBM
patients.
When tumors outgrow their blood supply, CSCs upregulate
pro-inflammatory proteins to help tumor survival under hypoxic
conditions (Tafani et al., 2011). In essence, CSCs play multi-faceted
roles in allowing a tumor to escape complete eradication. Specific
molecular markers that are capable of distinguishing CSCs from
normal stem cells or progenitor cells in the brain is not completely
resolved (Yilmaz et al., 2006; Calabrese et al., 2007). Therefore,
before CSCs can be clearly identified, therapeutic approaches des-
ignated to target them may actually cause more harm than good
to GBM patients.
EPIGENETIC MODIFICATIONS AND GBM RESISTANCE
TO TEMOZOLOMIDE
Temozolomide (TMZ) with or without radiation is the cur-
rent standard treatment for GBMs. Methylation of MGMT (O6-
methylguanine–DNA methyltransferase) promoter prevents gene
translation, and thereby prevents DNA repair in cancer cells. The
methylation status of the MGMT promoter is currently con-
sidered one of the strongest predictors of outcome and benefit
to TMZ treatment (Stupp et al., 2009). Mutant forms of meta-
bolic enzyme isocitrate dehydrogenase (IDH1) are found in a
great proportion of secondary gliomas, but are absent in the pri-
mary glioblastomas. The mutations are rarely found in primary
high-grade glioblastoma multiforme. Clinical data have demon-
strated that IDH1 may be a reliable prognostic marker for GBM.
Intriguingly, the presence of IDH1 mutation(s) in patients with
newly diagnosed GBMs showed prolonged, progression-free sur-
vival (Weller et al., 2009; Wick et al., 2009). GBMs with the CpG
island methylator phenotype (CIMP) have been shown to possess
extensive epigenetic aberrations to define a distinct subgroup of
gliomas (Noushmehr et al., 2010). Recent data showed that IDH
mutation and the CIMP phenotype are two very common fea-
tures in cancer (Turcan et al., 2012). IDH mutation is the cause of
CIMP and leads to the CIMP phenotype by stably reshaping the
epigenome. This genome-wide remodeling involves modulating
patterns of methylation, changing transcriptional programs, and
alteration of cell differentiation (Turcan et al., 2012). These data
highlight the interplay between genomic and epigenomic changes
in human cancers and may prove to be helpful in the develop-
ment of novel therapies for cancers. Shown in the Figure 1 is the
summary of MGMT repair and epigenetic modification in TMZ
treatment.
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FIGURE 1 | Summary of epigenetic modifications inTemozolomide
(TMZ)-treated GBMs. TMZ is an oral alkylating agent used for the
treatment of GBMs. TMZ causes cytotoxic DNA lesions such as
O6-methylguanine (O6-meG), and N3-methyladenine and N7-methylguanine
(N3-meA, N7-meG). The latter two lesions can be repaired by base excision
repair (BER) pathway. O6-meG DNA methyltransferase (MGMT) removes
the O6-alkylguanine and restores the guanine to normal, which promotes
tumor cell survival. When MGMT transfers and accepts an alkyl-group from
inhibitors O6-benzylguanine (O6-BG) and O6-(4-bromothenyl) guanine
(PaTrin-2), MGMT is inactivated and subjected to ubiquitin-mediated
degradation, thereby promoting cell death. MGMT functions may also be
impaired by gene deletion, altered therapeutic regimen, and suppression of
gene methylation promoter site. Notably, isocitrate dehydrogenase 1 (IDH1)
mutation is the cause of CpG island methylator phenotype (CIMP) via stably
reshaping the epigenome. IDH1 mutation by itself is also sufficient to
hypermethylate MGMT. MGMT hypermethylation causes DNA strand
breaks, apoptosis, autophagy, and tumor cell death. This is the mechanistic
rationale for the usage of the methylating therapeutic drugs.
Epigenetic inactivation of tumor suppressor genes has been
shown mainly in human malignant cancers. DKK1 gene expres-
sion, for example, is decreased in GBM tumor samples,
as compared with non-tumor brain tissues. Restoration of
DKK1 expression by a demethylating agent 5-azacytidine in
T98 GBM cells enhances their susceptibility to camptothecin-
and etoposide-induced apoptosis (Foltz et al., 2010), suggest-
ing that treatment of GBM cells with inhibitors of pro-
moter methylation for tumor suppressors facilitates drug effi-
cacy. Also, regulatory enzymes for epigenetic alterations may
be used for cancer therapy. When GBM cells were treated
with histone deacetylase (HDAC) inhibitors, accumulation of
methylated histone occurred. This histone methylation can
be removed by lysine specific demethylase 1 (LSD1). Intrigu-
ingly, simultaneous inhibition of HDACs and LSD1 leads to
synergistic apoptotic cell death in GBM cells (Singh et al.,
2011).
EPITHELIAL MESENCHYMAL TRANSITION AND DRUG
RESISTANCE IN GBMs
Epithelial mesenchymal transition (EMT) is a critical biologic
process that allows cancer cells to become metastatic. That is,
there is an increased cell migratory capacity, invasiveness, and
resistance to apoptosis (Kalluri and Neilson, 2003). EMT may
occur in tumor cells that have previously undergone genetic and
epigenetic changes, specifically in genes that favor clonal out-
growth, development of localized tumors, and enhancement of
carcinoma invasion and metastasis (Jin et al., 2011). Growth fac-
tors are known to induce EMT include members of the EGF family,
FGF, insulin-like growth factor, and MET (De Wever et al., 2008).
Transforming growth factor beta (TGF-β) is released by glioma
cells in large quantities in vitro. It has been implicated in the
malignant progression of glial tumors and the immune dysfunc-
tion in patients with GBM (Xu et al., 2009). TGF-β promotes
tumor-associated angiogenesis, tumor invasion, and suppression
of T cell-mediated immune responses (Xu et al., 2009). Proto-
oncogene MET (c-met ) amplification in human gliomas causes
increased activity of its downstream targets (e.g., Wnt/β-catenin
signaling) (Moon et al., 2000; Kim et al., 2013), and prolongs the
cancer survival (Halatsch et al., 2006). MET inhibitors appear to
lead to aberrant MET amplification in gliomas (Moon et al., 2000;
Chi et al., 2012). Dysregulation and prominent pathophysiological
roles of EGFR have been identified in GBMs. EGFR is overex-
pressed in about 40% of GBM cases, and half of these co-express a
mutated, activated subtype, EGFRvIII (Halatsch et al., 2006). Tar-
geted therapy against EFGR and EGFRvIII has no survival benefit
when compared to standard therapy. Stemness and invasiveness
of migrating glioma cells regulated by Frizzled 4 (FZD4), which
promotes expression of the EMT transition regulator SNAI1, are
considered as an important mechanism contributing to the fail-
ure of this approach (Jin et al., 2011; Pala et al., 2012). In its
complexity, EMT encompasses pathways that promote the con-
tinuous acquisition of malignant biological features by glioma
cells. A better understanding of the molecular mechanism of EMT
may help identify and rationally design combined therapeutic
regimes as well as selected patient subgroups that may benefit
from EGFR inhibition in GBMs (Tektonidis et al., 2011; Pala et al.,
2012).
POTENTIAL ROLE OF TIAF1 IN GBM PROGRESSION
We have recently demonstrated that accumulation of extracellu-
lar proteins, which are generated by both cancer cells and neural
cells, is critical for the self-protection, progression, and expan-
sion of brain metastatic cancer cells (Lee et al., 2010; Chang et al.,
2012). TGF-β-induced antiapoptotic factor (TIAF1) is an intra-
cellular protein, whose self-aggregation intracellularly may induce
generation of toxic amyloid beta (Aβ) and formation of amy-
loid fibrils (Lee et al., 2010; Chang et al., 2012). For example,
when TIAF1 undergoes self-aggregation, the aggregating pro-
tein may stimulate caspase activation, subsequent phosphoryla-
tion of membrane amyloid precursor protein (APP), breakdown
of APP, generation of toxic Aβ (e.g., Aβ42), and formation of
amyloid fibrils (Lee et al., 2010; Chang et al., 2012). Aβ does
not appear to cause cancer death. However, Aβ42 causes dam-
age to neuronal death or induces neurodegeneration. TIAF1 is
known to participate in the signaling of TGF-β/Smad proteins
(Chang et al., 1998, 2012; Khera and Chang, 2003; Lee et al.,
2010).
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FIGURE 2 | A postulated model for GBM malignancy. (A) U87-MG
glioma cells were inoculated in both flanks of nude mice. Two months
later, U87-MG cells were shown to metastasize to the lung. The solid
tumor lesion has overexpressed TIAF1 and amyloid fibrils, compared to
untreated normal lung. Specific antibodies against TIAF1 and amyloid fibril
were used (Lee et al., 2010; Chang et al., 2012). (B) TIAF1 expression is
frequently upregulated in the proliferating GBM cells, probably due to the
stimulation of micro-environmental factors in the brain. The intracellular
TIAF1 undergoes self-aggregation, may induce caspase activation, and
leads to phosphorylation and degradation of membrane amyloid precursor
protein (APP), generation of amyloid beta (Aβ), and formation of amyloid
fibrils (Lee et al., 2010; Chang et al., 2012). Secreted Aβ42 is toxic to
neurons. Also, Aβ42 undergoes self-polymerization and binds secreted
TIAF1, and the complexes are probably detrimental to neurons. Aβ is
indeed localized intracellularly. Cancer cells are resistant to the toxic effect
of polymerized TIAF1 and Aβ. The presence of intracellular aggregated
TIAF1 and amyloid fibrils in the tumor is likely to prevent the penetration
and efficacy of therapeutic drugs.
TIAF1 is shown to be significantly upregulated in the malignant
glioma cells in patients (Chang et al., 2012). A postulated model
for GBM malignancy is that upregulation of TIAF1 occurs in the
proliferating GBM stem cells, probably in response to extracellular
stress (Figure 2). TIAF1 is then becoming self-aggregated intra-
cellularly for leading to APP degradation and Aβ generation. Aβ is
then released to the extracellular matrix, or polymerizes further to
become amyloid fibrils, which are accumulated intracellularly. For
example, when metastatic U87-MG glioma cells were inoculated
in two subcutaneous sides in both flanks of nude mice, the cells
were metastatic to the lung. Both aggregated TIAF1 and amyloid
fibrils are overly expressed in the growing solid tumor (Chang
et al., 2012) (Figure 2). The intracellular TIAF1 and amyloid fib-
rils may provide resistance to drug penetration into cancer cells,
thereby promoting cancer cell survival.
CONCLUSION
Human GBM is one of most challenging tumors to treat. Fail-
ure of therapeutic approaches to target specific signaling trans-
duction or glioma-relevant mutation pathway genes in GBMs is
mainly due to reactivation of certain common signaling pathways
that are involved in cell growth and proliferation. Unpredictable
clonal growth and specific gene amplification occur in CSCs. CSCs
may also participate in treatment-induced evasive and/or intrinsic
resistance and therefore therapeutic outcomes.
Ongoing “normal” epigenetic processes are associated with dif-
ferentiation (Gan et al., 2007). Emerging data suggest that GBM
patients with epigenetic MGMT methylation respond to TZM
better and have prolonged survival than the patients without it.
However, it is reported that patients without MGMT methylation
may also be beneficial to TZM treatment (von Deimling et al.,
2011), which suggests multiple mechanisms are involved in GBM
pathogenesis. Direct genetic disruptions within the core epigenetic
machinery may occur, such as the recently identified mutations
within IDH1/2 and variant histone genes H3.3/H3F3A (Carén
et al., 2012). IDH1 mutation alone is enough for the development
of the glioma hypermethylate phenotype (Turcan et al., 2012).
Therefore, IDH1 may be used as a prognostic marker in low-grade
and high-grade gliomas and aid in the differentiation and diag-
nosis of various tumors with histologic ambiguity. Insights into
MGMT, IDH1 mutation may help decode GBM resistance in both
primary and secondary GBMs. EMT helps the continuous acqui-
sition of malignant phenotype in GBMs, and may also contribute
to the failure of targeted therapy.
In summary, development of GBM resistance involves multi-
ple mechanisms with interplayed redundancies that determine the
survival or death of cancer. Designing therapeutic regimes that
target the aforementioned potential resistance mechanisms may
likely be the primary focus of GBM treatment in the future.
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